Skip to main content
. 2014 Aug 7;21(10):3261–3267. doi: 10.1245/s10434-014-3908-y

Table 3.

Neoadjuvant treatment received by BluePrint/MammaPrint molecular subtyping

Treatment BluePrint/MammaPrint Total
Luminal A Luminal B HER2 Basal
NCT 37 116 4 123 280
NCT/trastuzumab 7a 29b 70 17c 123
NCT/NET 0 3 0 0 3
NET 15 5 0 0 20
Total 59 153 74 140 426

a7 IHC/FISH HER2+ patients

b25 IHC/FISH HER2+ patients, 2 IHC/FISH HER2 equivocal patients, and 2 with a positive mRNA HER2 read out

c16 IHC/FISH HER2+ patients and 1 IHC/FISH HER2 equivocal patient